BRIEF-Amicus expands pipeline with new program for CDKl5 deficiency By: Reuters: Company News July 06, 2016 at 16:17 PM EDT * Acquisition of Miamed does not impact previous full-year 2016 net cash spend guidance of $135 million to $155 million Read More >> Related Stocks: Amicus Therapeutics